Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694218 | 1.00 | TLR7 (0.44) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL5523405 | 0.98 | RAB9A (0.44) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL10587438 | 0.97 | ALDH1A1 (0.46) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| SCHEMBL28312743 | 0.95 | TLR7 (0.44) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| Isobutanol SCHEMBL9386343 | 0.87 | TLR7 (0.47) | TLR7TLR8ADORA2AADRA1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL4984421 | 0.87 | TLR7 (0.40) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| Trifluoroacetic Acid SCHEMBL7096569 | 0.87 | TLR7 (0.40) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| SCHEMBL14127897 | 0.85 | ADORA3 (0.36) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| SCHEMBL14127899 | 0.82 | SMN1; SMN2 (0.39) | TLR7TLR8ADORA3ADORA2AADORA1 | |
| SCHEMBL6099467 | 0.82 | MAPT (0.42) | TLR7ADORA3ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368155-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2024-11-07 | — | — | US | claimed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | claimed |
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | claimed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| EP-3849615-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | Silverback Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| WO-2020056008-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | claimed |
| EP-3344262-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | Innate Tumor Immunity, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| US-20170266297-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOQUINOLIN(AMINES) AND DERIVATIVES THEREOF SUITABLE FOR LOCAL ADMINISTRATION | TELORMEDIX SA (CH) | 2017-09-21 | — | — | US | claimed |
| EP-3176169-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | Yu, Chongxi (US) | 2017-06-07 | — | — | EP | claimed |
| EP-0636031-A1 | VACCINE ADJUVANT. | MINNESOTA MINING & MFG (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1995002598-A1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-01-26 | — | — | WO | claimed |
| WO-1994017043-A1 | PROCESS FOR PREPARING QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-08-04 | — | — | WO | claimed |
| EP-0575549-A1 | PROCESS FOR IMIDAZO 4,5-c]QUINOLIN-4-AMINES. | MINNESOTA MINING & MFG (US) | 1993-12-29 | — | — | EP | claimed |
| WO-1993020847-A1 | VACCINE ADJUVANT | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| US-5175296-A | Reacting 1H-imidazolo(4,5-c)quinolin-5N-oxide with organic isocyanate; hydrolysis | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992015581-A1 | PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0385630-A2 | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals | RIKER LABORATORIES, INC. (US) | 1990-09-05 | — | — | EP | claimed |
| EP-0145340-B1 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0145340-A2 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266297-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOQUINOLIN(AMINES) AND DERIVATIVES THEREOF SUITABLE FOR LOCAL ADMINISTRATION | IDO2, IDO1, TLR5 | TLR7 6/4885TLR8 27/4885ADORA3 84/4885 |
| US-20240368155-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885ADORA3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.